Scholarlink

Purpose <p>Precise quantification of myocardial blood flow (MBF) and flow reserve (MFR) in <sup>18</sup>F-flurpiridaz PET significantly relies on motion correction (MC). However, the manual frame-by-frame correction leads to significant inter-observer variability, time-consuming, and requires significant experience. We propose a deep learning (DL) framework for automatic MC of <sup>18</sup>F-flurpiridaz PET.</p> Methods <p>The method employs a 3D-ResNet based architecture that takes 3D PET volumes and outputs motion vectors. It was validated using 5-fold cross-validation on data from 32-sites of a Phase-III clinical trial (NCT01347710). Manual corrections from two experienced operators served as ground truth, and data augmentation using simulated vectors enhanced training robustness. The study compared the DL approach to both manual and standard non-AI automatic MC methods, assessing agreement and diagnostic accuracy using minimal segmental stress MBF and MFR.</p> Results <p>The area under the receiver operating characteristic curves (AUC) for significant CAD were comparable between DL-MC stress MBF, manual-MC stress MBF from Operators (AUC = 0.897, 0.892 and 0.889, respectively; <i>p</i> &gt; 0.05), standard non-AI automatic MC (AUC = 0.877; <i>p</i> &gt; 0.05) and significantly higher than No-MC (AUC = 0.835; <i>p</i> &lt; 0.05). Similar findings were observed with MFR. The 95% confidence limits for agreement with the operator were ± 0.49 (mean difference = 0.00) for MFR and ± 0.24&#xa0;ml/g/min (mean difference = 0.00) for stress MBF.</p> Conclusion <p>DL-MC is significantly faster but diagnostically comparable to manual-MC. The quantitative results obtained with DL-MC for stress MBF and MFR are in excellent agreement with those manually corrected by experienced operators compared to standard non-AI automatic MC in patients undergoing <sup>18</sup>F-flurpiridaz PET-MPI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dynamic frame-by-frame motion correction for 18F-flurpiridaz PET-MPI using convolution neural network

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月20日

查看全文
  • Meghana Urs,
  • Aditya Killekar,
  • Valerie Builoff,
  • Mark Lemley,
  • Chih-Chun Wei,
  • Giselle Ramirez,
  • Paul Kavanagh,
  • Christopher Buckley,
  • Piotr J. Slomka

摘要

Purpose

Precise quantification of myocardial blood flow (MBF) and flow reserve (MFR) in 18F-flurpiridaz PET significantly relies on motion correction (MC). However, the manual frame-by-frame correction leads to significant inter-observer variability, time-consuming, and requires significant experience. We propose a deep learning (DL) framework for automatic MC of 18F-flurpiridaz PET.

Methods

The method employs a 3D-ResNet based architecture that takes 3D PET volumes and outputs motion vectors. It was validated using 5-fold cross-validation on data from 32-sites of a Phase-III clinical trial (NCT01347710). Manual corrections from two experienced operators served as ground truth, and data augmentation using simulated vectors enhanced training robustness. The study compared the DL approach to both manual and standard non-AI automatic MC methods, assessing agreement and diagnostic accuracy using minimal segmental stress MBF and MFR.

Results

The area under the receiver operating characteristic curves (AUC) for significant CAD were comparable between DL-MC stress MBF, manual-MC stress MBF from Operators (AUC = 0.897, 0.892 and 0.889, respectively; p > 0.05), standard non-AI automatic MC (AUC = 0.877; p > 0.05) and significantly higher than No-MC (AUC = 0.835; p < 0.05). Similar findings were observed with MFR. The 95% confidence limits for agreement with the operator were ± 0.49 (mean difference = 0.00) for MFR and ± 0.24 ml/g/min (mean difference = 0.00) for stress MBF.

Conclusion

DL-MC is significantly faster but diagnostically comparable to manual-MC. The quantitative results obtained with DL-MC for stress MBF and MFR are in excellent agreement with those manually corrected by experienced operators compared to standard non-AI automatic MC in patients undergoing 18F-flurpiridaz PET-MPI.